$MRNA
Moderna, Inc.

2020 Q4 Form 10-Q Financial Statement

#000168285220000023 Filed on October 30, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $570.7M $157.0M $17.05M
YoY Change 3960.48% 821.04% -59.18%
Cost Of Revenue $7.900M $0.00
YoY Change
Gross Profit $562.8M $157.0M
YoY Change
Gross Profit Margin 98.62% 100.0%
Selling, General & Admin $79.00M $48.50M $28.20M
YoY Change 208.59% 71.99% 52.43%
% of Gross Profit 14.04% 30.89%
Research & Development $758.9M $344.0M $119.6M
YoY Change 545.87% 187.54% 9.71%
% of Gross Profit 134.84% 219.11%
Depreciation & Amortization $7.800M $8.000M $7.300M
YoY Change -13.33% 9.59% 12.31%
% of Gross Profit 1.39% 5.1%
Operating Expenses $837.9M $393.0M $147.8M
YoY Change 479.42% 165.9% 15.86%
Operating Profit -$275.1M -$235.0M -$130.8M
YoY Change 110.71% 79.71% 52.37%
Interest Expense $900.0K $2.900M $7.700M
YoY Change -85.48% -62.34% 22.22%
% of Operating Profit
Other Income/Expense, Net $3.100M -$3.000M -$1.881M
YoY Change -875.0% 59.49% 82.27%
Pretax Income -$271.0M -$232.0M -$123.4M
YoY Change 119.79% 88.02% 53.61%
Income Tax $1.500M $1.000M -$178.0K
% Of Pretax Income
Net Earnings -$272.5M -$233.0M -$123.2M
YoY Change 121.36% 89.1% 53.38%
Net Earnings / Revenue -47.75% -148.41% -722.84%
Basic Earnings Per Share -$0.59
Diluted Earnings Per Share -$686.7K -$0.59 -$372.4K
COMMON SHARES
Basic Shares Outstanding 395.7M shares 395.0M shares 330.2M shares
Diluted Shares Outstanding 395.0M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.608B $3.277B $1.059B
YoY Change 317.72% 209.55% -1.26%
Cash & Equivalents $2.624B $1.506B $173.7M
Short-Term Investments $1.984B $1.771B $884.8M
Other Short-Term Assets $11.00M $87.00M $11.00M
YoY Change 22.22% 690.91% -60.71%
Inventory $47.00M
Prepaid Expenses $15.65M $9.730M
Receivables $1.391B $190.5M $2.800M
Other Receivables $20.00M $22.00M $17.00M
Total Short-Term Assets $6.298B $3.577B $1.094B
YoY Change 457.94% 226.85% -2.11%
LONG-TERM ASSETS
Property, Plant & Equipment $387.0M $369.0M $203.7M
YoY Change 34.38% 81.16% -1.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $639.0M $692.0M $280.0M
YoY Change 299.38% 147.14% 86.67%
Other Assets $2.000M $2.047M $2.094M
YoY Change 3.57% -2.24% -85.04%
Total Long-Term Assets $1.039B $1.074B $496.4M
YoY Change 125.57% 116.28% 33.81%
TOTAL ASSETS
Total Short-Term Assets $6.298B $3.577B $1.094B
Total Long-Term Assets $1.039B $1.074B $496.4M
Total Assets $7.337B $4.651B $1.591B
YoY Change 361.61% 192.34% 6.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.00M $20.52M $11.74M
YoY Change 153.88% 74.84% -51.1%
Accrued Expenses $470.0M $208.8M $60.08M
YoY Change 594.73% 247.6% 33.51%
Deferred Revenue $3.867B $1.235B $70.19M
YoY Change 6008.04% 1658.78%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $24.00M
YoY Change
Total Short-Term Liabilities $4.389B $1.474B $147.8M
YoY Change 2966.76% 896.71% -20.52%
LONG-TERM LIABILITIES
Long-Term Debt $110.0M $109.0M $34.00M
YoY Change 182.05% 220.59% 25.93%
Other Long-Term Liabilities $3.000M $2.183M $161.0K
YoY Change 2073.91% 1255.9% -99.92%
Total Long-Term Liabilities $3.000M $2.183M $161.0K
YoY Change 2073.91% 1255.9% -99.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.389B $1.474B $147.8M
Total Long-Term Liabilities $3.000M $2.183M $161.0K
Total Liabilities $4.776B $1.891B $339.1M
YoY Change 1051.92% 457.69% -17.9%
SHAREHOLDERS EQUITY
Retained Earnings -$2.244B -$1.970B -$1.370B
YoY Change 49.95% 43.84%
Common Stock $0.00 $40.00K $33.00K
YoY Change -100.0% 21.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.561B $2.760B $1.248B
YoY Change
Total Liabilities & Shareholders Equity $7.337B $4.651B $1.591B
YoY Change 361.61% 192.34% 6.84%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$272.5M -$233.0M -$123.2M
YoY Change 121.36% 89.1% 53.38%
Depreciation, Depletion And Amortization $7.800M $8.000M $7.300M
YoY Change -13.33% 9.59% 12.31%
Cash From Operating Activities $1.264B $892.8M -$107.0M
YoY Change -1375.78% -934.39% 33.42%
INVESTING ACTIVITIES
Capital Expenditures -$23.30M -$19.20M -$6.700M
YoY Change 247.76% 186.57% -74.33%
Acquisitions
YoY Change
Other Investing Activities -$166.8M -$1.159B $120.1M
YoY Change -221.75% -1065.03% -15.6%
Cash From Investing Activities -$190.1M -$1.178B $113.4M
YoY Change -245.78% -1139.07% -2.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 44.10M 29.70M 15.80M
YoY Change 43.18% 87.97% -266.32%
NET CHANGE
Cash From Operating Activities 1.264B 892.8M -107.0M
Cash From Investing Activities -190.1M -1.178B 113.4M
Cash From Financing Activities 44.10M 29.70M 15.80M
Net Change In Cash 1.118B -255.8M 22.20M
YoY Change 1700.81% -1252.25% -15.59%
FREE CASH FLOW
Cash From Operating Activities $1.264B $892.8M -$107.0M
Capital Expenditures -$23.30M -$19.20M -$6.700M
Free Cash Flow $1.288B $912.0M -$100.3M
YoY Change -1493.51% -1009.27% 85.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001682852
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Local Phone Number
LocalPhoneNumber
714-6500
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38753
dei Entity Registrant Name
EntityRegistrantName
Moderna, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3467528
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Technology Square
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Trading Symbol
TradingSymbol
MRNA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
395710105 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1505581000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235876000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1770721000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
867124000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
190501000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5369000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
109376000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19403000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
3577211000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1128804000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
691969000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
159987000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
276909000 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1032000 USD
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1032000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
201495000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91684000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86414000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11053000 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10791000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2047000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1931000 USD
CY2020Q3 us-gaap Assets
Assets
4650873000 USD
CY2019Q4 us-gaap Assets
Assets
1589422000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
20521000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7090000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
208832000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67652000 USD
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1234506000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
63310000 USD
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9702000 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5063000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1473561000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
143115000 USD
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
207768000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
138995000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98954000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93675000 USD
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
108609000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
38689000 USD
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2183000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
138000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
1891075000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
414612000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
395390672 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
395390672 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
336536985 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
336536985 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
40000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
34000 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4726007000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2669426000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4784000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1804000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1971033000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1496454000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2759798000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1174810000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4650873000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1589422000 USD
CY2020Q3 us-gaap Revenues
Revenues
157910000 USD
CY2019Q3 us-gaap Revenues
Revenues
17046000 USD
us-gaap Revenues
Revenues
232650000 USD
us-gaap Revenues
Revenues
46154000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
344486000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119637000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
611479000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
378355000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48541000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28173000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
109277000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-488106000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
83913000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
393027000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
147810000 USD
us-gaap Operating Expenses
OperatingExpenses
720756000 USD
us-gaap Operating Expenses
OperatingExpenses
462268000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-235117000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-130764000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-416114000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5571000 USD
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9252000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
20515000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
30546000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3226000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1881000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5910000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5689000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-232772000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-123393000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-473501000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-391257000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
864000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-178000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1078000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-526000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233636000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-123215000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474579000 USD
us-gaap Net Income Loss
NetIncomeLoss
-390731000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-211000 USD
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
394682744 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
330769341 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
376174283 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
329592322 shares
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233636000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-123215000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474579000 USD
us-gaap Net Income Loss
NetIncomeLoss
-390731000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
25000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1173000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3683000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
168000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1878000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4243000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
79000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-1102000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
93000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3472000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
89000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2980000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4150000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-237108000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123126000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-471599000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-386581000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
2946885000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26815000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23206000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3472000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233636000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2759798000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1334960000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15554000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20804000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
89000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-123215000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
1248192000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1174810000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2086000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1852759000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
133369000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2917000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67542000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
2980000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474579000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2759798000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1530241000 USD
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19541000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60796000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4150000 USD
us-gaap Net Income Loss
NetIncomeLoss
-390731000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
1248192000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474579000 USD
us-gaap Net Income Loss
NetIncomeLoss
-390731000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
67542000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
60796000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23545000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22046000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5053000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
6684000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
3428000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-287000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-70000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
185132000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4369000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
67994000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1813000 USD
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
13117000 USD
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
7970000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13633000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19185000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
132374000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8253000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1239969000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-32795000 USD
mrna Operating Lease Liabilities
OperatingLeaseLiabilities
14417000 USD
mrna Operating Lease Liabilities
OperatingLeaseLiabilities
13475000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-153000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
762682000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-359946000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
2326141000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
949277000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
748152000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
747846000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
140337000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
81030000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44147000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24892000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1481799000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-145293000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1852759000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
133369000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
19541000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2917000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0 USD
mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
39000 USD
mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
741000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1989084000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20282000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1269967000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-484957000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247699000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
670491000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1517666000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
185534000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13280000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1863000 USD
mrna Leasehold Improvements Incurred But Not Yet Reimbursed
LeaseholdImprovementsIncurredButNotYetReimbursed
0 USD
mrna Leasehold Improvements Incurred But Not Yet Reimbursed
LeaseholdImprovementsIncurredButNotYetReimbursed
6310000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1970000000 USD
us-gaap Use Of Estimates
UseOfEstimates
We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, and useful lives of long-lived assets. We base our estimates on historical experience and on various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
119637000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
378355000 USD
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28173000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
83913000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
147810000 USD
us-gaap Operating Expenses
OperatingExpenses
462268000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-130764000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-416114000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1881000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5689000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-123393000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-391257000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-123215000 USD
us-gaap Net Income Loss
NetIncomeLoss
-390731000 USD
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
us-gaap Net Income Loss
NetIncomeLoss
-390731000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22046000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1813000 USD
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
7970000 USD
mrna Operating Lease Liabilities
OperatingLeaseLiabilities
13475000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-153000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-359946000 USD
mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
741000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20282000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1505581000 USD
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173711000 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1032000 USD
CY2019Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1032000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11053000 USD
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
10791000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1517666000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
185534000 USD
CY2020Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
104945000 USD
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
-5500000 USD
CY2020Q3 mrna Number Of Additional Doses Of Vaccine
NumberOfAdditionalDosesOfVaccine
100000000 dose
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1766834000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1770721000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
689891000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
691969000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2456725000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
2462690000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
509000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
759483000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0 option
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
509000 USD
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
759483000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
40000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
85161000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
40000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
85161000 USD
CY2019Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
19 option
CY2020Q3 mrna Other Prepaid Expense Manufacturing
OtherPrepaidExpenseManufacturing
23990000 USD
CY2019Q4 mrna Other Prepaid Expense Manufacturing
OtherPrepaidExpenseManufacturing
0 USD
CY2020Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
62434000 USD
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
8475000 USD
CY2020Q3 mrna Tenant Incentives Receivables Current
TenantIncentivesReceivablesCurrent
12941000 USD
CY2019Q4 mrna Tenant Incentives Receivables Current
TenantIncentivesReceivablesCurrent
4093000 USD
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
10011000 USD
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
6835000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
109376000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19403000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
388899000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
296079000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
111990000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
94584000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
276909000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
201495000 USD
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8500000 USD
CY2019Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7300000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
23500000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000000.0 USD
CY2020Q3 mrna Accrued Clinical Trials
AccruedClinicalTrials
44554000 USD
CY2019Q4 mrna Accrued Clinical Trials
AccruedClinicalTrials
6291000 USD
CY2020Q3 mrna Accrued Development Operation
AccruedDevelopmentOperation
24187000 USD
CY2019Q4 mrna Accrued Development Operation
AccruedDevelopmentOperation
2567000 USD
CY2020Q3 mrna Accrued Manufacturing
AccruedManufacturing
14029000 USD
CY2019Q4 mrna Accrued Manufacturing
AccruedManufacturing
5872000 USD
CY2020Q3 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
64439000 USD
CY2019Q4 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
21465000 USD
CY2019Q4 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
21465000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
48788000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27428000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
202305000 USD
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
1293370000 USD
mrna Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
53401000 USD
CY2020Q3 mrna Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
12835000 USD
CY2019Q4 mrna Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
4029000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
208832000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67652000 USD
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1442274000 USD
CY2020Q3 mrna Operating Lease Number Of Properties
OperatingLeaseNumberOfProperties
2 campus
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91684000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86414000 USD
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
55503000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
9544000 USD
CY2020Q3 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
147187000 USD
CY2019Q4 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
95958000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4731000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3584000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98954000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93675000 USD
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
108609000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
38689000 USD
CY2020Q3 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
207563000 USD
CY2019Q4 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
132364000 USD
CY2020Q3 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
212294000 USD
CY2019Q4 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
135948000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
3962000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
3962000 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
3872000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
12977000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
11614000 USD
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
368000 USD
CY2020Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
368000 USD
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
73000 USD
CY2019Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
73000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
553000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
219000 USD
CY2020Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2843000 USD
CY2020Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2843000 USD
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1644000 USD
CY2019Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1644000 USD
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
6385000 USD
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4901000 USD
CY2020Q3 mrna Finance Lease Cost
FinanceLeaseCost
3211000 USD
CY2019Q3 mrna Finance Lease Cost
FinanceLeaseCost
1717000 USD
mrna Finance Lease Cost
FinanceLeaseCost
6938000 USD
mrna Finance Lease Cost
FinanceLeaseCost
5120000 USD
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1430000 USD
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1430000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
3618000 USD
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1120000 USD
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1120000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
3495000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
11314000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
11396000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
5383000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
4161000 USD
mrna Right Of Use Assets Reduced Through Lease Modifications And Reassessments
RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
6755000 USD
mrna Right Of Use Assets Reduced Through Lease Modifications And Reassessments
RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments
16242000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
17107000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
26839000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
46495000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 USD
mrna Lessee Finance Lease Expense
LesseeFinanceLeaseExpense
39000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1858000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
15492000 USD
mrna Lessee Finance Lease Expense
LesseeFinanceLeaseExpense
741000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2770000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
11634000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
15913000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
11848000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16008000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
12054000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16168000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
12279000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
110167000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
440552000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
176518000 USD
CY2020Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
490225000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
72833000 USD
CY2020Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
381616000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
103685000 USD
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
108609000 USD
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
775000000 shares
CY2018Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
509352795 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
67500000 shares
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67542000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
45536915 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2019Q4 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
7.35
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
286310000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4809336 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.10
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10613303 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.57
mrna Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
6.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
2471131 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.78
mrna Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue
10.39
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
37261817 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.49
CY2020Q3 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
8.82
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2022154000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
18348695 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.96
CY2020Q3 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
5.61
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1097117000 USD
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
18913122 shares
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
21.86
CY2020Q3 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
11.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
926598000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10600000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
434900000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
133400000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60796000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23206000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20804000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67542000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
60796000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23206000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20804000 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
236900000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M23D
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1100000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233636000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-123215000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474579000 USD
us-gaap Net Income Loss
NetIncomeLoss
-390731000 USD
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
394682744 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
330769341 shares
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
376174283 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
329592322 shares
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.19
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39433994 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50643406 shares

Files In Submission

Name View Source Status
0001682852-20-000023-index-headers.html Edgar Link pending
0001682852-20-000023-index.html Edgar Link pending
0001682852-20-000023.txt Edgar Link pending
0001682852-20-000023-xbrl.zip Edgar Link pending
a4exhibit3119302020.htm Edgar Link pending
a5exhibit3129302020.htm Edgar Link pending
a6exhibit3219302020.htm Edgar Link pending
exhibit101.htm Edgar Link pending
exhibit101001.jpg Edgar Link pending
exhibit101002.jpg Edgar Link pending
exhibit101003.jpg Edgar Link pending
exhibit101004.jpg Edgar Link pending
exhibit101005.jpg Edgar Link pending
exhibit101006.jpg Edgar Link pending
exhibit101007.jpg Edgar Link pending
exhibit101008.jpg Edgar Link pending
exhibit101009.jpg Edgar Link pending
exhibit101010.jpg Edgar Link pending
exhibit101011.jpg Edgar Link pending
exhibit101012.jpg Edgar Link pending
exhibit101013.jpg Edgar Link pending
exhibit101014.jpg Edgar Link pending
exhibit101015.jpg Edgar Link pending
exhibit101016.jpg Edgar Link pending
exhibit101017.jpg Edgar Link pending
exhibit101018.jpg Edgar Link pending
exhibit101019.jpg Edgar Link pending
exhibit101020.jpg Edgar Link pending
exhibit101021.jpg Edgar Link pending
exhibit101022.jpg Edgar Link pending
exhibit101023.jpg Edgar Link pending
exhibit101024.jpg Edgar Link pending
exhibit101025.jpg Edgar Link pending
exhibit101026.jpg Edgar Link pending
exhibit101027.jpg Edgar Link pending
exhibit101028.jpg Edgar Link pending
exhibit101029.jpg Edgar Link pending
exhibit101030.jpg Edgar Link pending
exhibit101031.jpg Edgar Link pending
exhibit101032.jpg Edgar Link pending
exhibit101033.jpg Edgar Link pending
exhibit101034.jpg Edgar Link pending
exhibit101035.jpg Edgar Link pending
exhibit101036.jpg Edgar Link pending
exhibit101037.jpg Edgar Link pending
exhibit101038.jpg Edgar Link pending
exhibit101039.jpg Edgar Link pending
exhibit101040.jpg Edgar Link pending
exhibit101041.jpg Edgar Link pending
exhibit101042.jpg Edgar Link pending
exhibit101043.jpg Edgar Link pending
exhibit101044.jpg Edgar Link pending
exhibit101045.jpg Edgar Link pending
exhibit101046.jpg Edgar Link pending
exhibit101047.jpg Edgar Link pending
exhibit101048.jpg Edgar Link pending
exhibit101049.jpg Edgar Link pending
exhibit101050.jpg Edgar Link pending
exhibit101051.jpg Edgar Link pending
exhibit101052.jpg Edgar Link pending
exhibit101053.jpg Edgar Link pending
exhibit101054.jpg Edgar Link pending
exhibit101055.jpg Edgar Link pending
exhibit101056.jpg Edgar Link pending
exhibit101057.jpg Edgar Link pending
exhibit101058.jpg Edgar Link pending
exhibit101059.jpg Edgar Link pending
exhibit101060.jpg Edgar Link pending
exhibit101061.jpg Edgar Link pending
exhibit101062.jpg Edgar Link pending
exhibit101063.jpg Edgar Link pending
exhibit101064.jpg Edgar Link pending
exhibit101065.jpg Edgar Link pending
exhibit101066.jpg Edgar Link pending
exhibit101067.jpg Edgar Link pending
exhibit101068.jpg Edgar Link pending
exhibit101069.jpg Edgar Link pending
exhibit101070.jpg Edgar Link pending
exhibit101071.jpg Edgar Link pending
exhibit101072.jpg Edgar Link pending
exhibit101073.jpg Edgar Link pending
exhibit101074.jpg Edgar Link pending
exhibit101075.jpg Edgar Link pending
exhibit101076.jpg Edgar Link pending
exhibit101077.jpg Edgar Link pending
exhibit101078.jpg Edgar Link pending
exhibit101079.jpg Edgar Link pending
exhibit101080.jpg Edgar Link pending
exhibit101081.jpg Edgar Link pending
exhibit101082.jpg Edgar Link pending
exhibit101083.jpg Edgar Link pending
exhibit101084.jpg Edgar Link pending
exhibit101085.jpg Edgar Link pending
exhibit101086.jpg Edgar Link pending
exhibit101087.jpg Edgar Link pending
exhibit101088.jpg Edgar Link pending
exhibit101089.jpg Edgar Link pending
exhibit101090.jpg Edgar Link pending
exhibit101091.jpg Edgar Link pending
exhibit101092.jpg Edgar Link pending
exhibit101093.jpg Edgar Link pending
exhibit101094.jpg Edgar Link pending
exhibit101095.jpg Edgar Link pending
exhibit101096.jpg Edgar Link pending
exhibit101097.jpg Edgar Link pending
exhibit101098.jpg Edgar Link pending
exhibit101099.jpg Edgar Link pending
exhibit101100.jpg Edgar Link pending
exhibit103.htm Edgar Link pending
exhibit103001.jpg Edgar Link pending
exhibit103002.jpg Edgar Link pending
exhibit103003.jpg Edgar Link pending
exhibit103004.jpg Edgar Link pending
exhibit103005.jpg Edgar Link pending
exhibit103006.jpg Edgar Link pending
exhibit103007.jpg Edgar Link pending
exhibit103008.jpg Edgar Link pending
exhibit103009.jpg Edgar Link pending
exhibit103010.jpg Edgar Link pending
exhibit103011.jpg Edgar Link pending
exhibit103012.jpg Edgar Link pending
exhibit103013.jpg Edgar Link pending
exhibit103014.jpg Edgar Link pending
exhibit103015.jpg Edgar Link pending
exhibit103016.jpg Edgar Link pending
exhibit103017.jpg Edgar Link pending
exhibit103018.jpg Edgar Link pending
exhibit103019.jpg Edgar Link pending
exhibit103020.jpg Edgar Link pending
exhibit103021.jpg Edgar Link pending
exhibit103022.jpg Edgar Link pending
exhibit103023.jpg Edgar Link pending
exhibit103024.jpg Edgar Link pending
exhibit103025.jpg Edgar Link pending
exhibit103026.jpg Edgar Link pending
exhibit103027.jpg Edgar Link pending
exhibit103028.jpg Edgar Link pending
exhibit103029.jpg Edgar Link pending
exhibit103030.jpg Edgar Link pending
exhibit103031.jpg Edgar Link pending
exhibit103032.jpg Edgar Link pending
exhibit103033.jpg Edgar Link pending
exhibit103034.jpg Edgar Link pending
exhibit103035.jpg Edgar Link pending
exhibit103036.jpg Edgar Link pending
exhibit103037.jpg Edgar Link pending
exhibit103038.jpg Edgar Link pending
exhibit103039.jpg Edgar Link pending
exhibit103040.jpg Edgar Link pending
exhibit103041.jpg Edgar Link pending
exhibit103042.jpg Edgar Link pending
exhibit103043.jpg Edgar Link pending
exhibit103044.jpg Edgar Link pending
exhibit103045.jpg Edgar Link pending
exhibit103046.jpg Edgar Link pending
exhibit103047.jpg Edgar Link pending
exhibit103048.jpg Edgar Link pending
exhibit103049.jpg Edgar Link pending
exhibit103050.jpg Edgar Link pending
exhibit103051.jpg Edgar Link pending
exhibit103052.jpg Edgar Link pending
exhibit103053.jpg Edgar Link pending
exhibit103054.jpg Edgar Link pending
exhibit103055.jpg Edgar Link pending
exhibit103056.jpg Edgar Link pending
exhibit103057.jpg Edgar Link pending
exhibit103058.jpg Edgar Link pending
exhibit103059.jpg Edgar Link pending
exhibit103060.jpg Edgar Link pending
exhibit103061.jpg Edgar Link pending
exhibit103062.jpg Edgar Link pending
exhibit103063.jpg Edgar Link pending
exhibit103064.jpg Edgar Link pending
exhibit103065.jpg Edgar Link pending
exhibit103066.jpg Edgar Link pending
exhibit103067.jpg Edgar Link pending
exhibit103068.jpg Edgar Link pending
exhibit103069.jpg Edgar Link pending
exhibit103070.jpg Edgar Link pending
exhibit103071.jpg Edgar Link pending
exhibit103072.jpg Edgar Link pending
exhibit103073.jpg Edgar Link pending
exhibit103074.jpg Edgar Link pending
exhibit103075.jpg Edgar Link pending
exhibit103076.jpg Edgar Link pending
exhibit103077.jpg Edgar Link pending
exhibit103078.jpg Edgar Link pending
exhibit103079.jpg Edgar Link pending
exhibit103080.jpg Edgar Link pending
exhibit103081.jpg Edgar Link pending
exhibit103082.jpg Edgar Link pending
exhibit103083.jpg Edgar Link pending
exhibit103084.jpg Edgar Link pending
exhibit103085.jpg Edgar Link pending
exhibit103086.jpg Edgar Link pending
exhibit103087.jpg Edgar Link pending
exhibit103088.jpg Edgar Link pending
exhibit103089.jpg Edgar Link pending
exhibit103090.jpg Edgar Link pending
exhibit103091.jpg Edgar Link pending
exhibit103092.jpg Edgar Link pending
exhibit103093.jpg Edgar Link pending
exhibit103094.jpg Edgar Link pending
exhibit103095.jpg Edgar Link pending
exhibit103096.jpg Edgar Link pending
exhibit103097.jpg Edgar Link pending
exhibit103098.jpg Edgar Link pending
exhibit103099.jpg Edgar Link pending
exhibit103100.jpg Edgar Link pending
exhibit103101.jpg Edgar Link pending
exhibit103102.jpg Edgar Link pending
exhibit103103.jpg Edgar Link pending
exhibit103104.jpg Edgar Link pending
exhibit103105.jpg Edgar Link pending
exhibit103106.jpg Edgar Link pending
exhibit103107.jpg Edgar Link pending
exhibit103108.jpg Edgar Link pending
exhibit103109.jpg Edgar Link pending
exhibit103110.jpg Edgar Link pending
exhibit103111.jpg Edgar Link pending
exhibit103112.jpg Edgar Link pending
exhibit103113.jpg Edgar Link pending
exhibit103114.jpg Edgar Link pending
exhibit103115.jpg Edgar Link pending
exhibit103116.jpg Edgar Link pending
exhibit103117.jpg Edgar Link pending
exhibit103118.jpg Edgar Link pending
exhibit103119.jpg Edgar Link pending
exhibit103120.jpg Edgar Link pending
exhibit103121.jpg Edgar Link pending
exhibit103122.jpg Edgar Link pending
exhibit103123.jpg Edgar Link pending
exhibit103124.jpg Edgar Link pending
exhibit103125.jpg Edgar Link pending
exhibit103126.jpg Edgar Link pending
exhibit103127.jpg Edgar Link pending
exhibit103128.jpg Edgar Link pending
exhibit103129.jpg Edgar Link pending
exhibit103130.jpg Edgar Link pending
exhibit103131.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_31.jpg Edgar Link pending
image_41.jpg Edgar Link pending
lonzamodernagltafullye.htm Edgar Link pending
MetaLinks.json Edgar Link pending
mrna-20200930.htm Edgar Link pending
mrna-20200930.xsd Edgar Link pending
mrna-20200930_cal.xml Edgar Link unprocessable
mrna-20200930_def.xml Edgar Link unprocessable
mrna-20200930_g1.jpg Edgar Link pending
mrna-20200930_g2.jpg Edgar Link pending
mrna-20200930_g3.jpg Edgar Link pending
mrna-20200930_htm.xml Edgar Link completed
mrna-20200930_lab.xml Edgar Link unprocessable
mrna-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending